Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Hospitals & Diagnostics
    • Daiichi-Ranbaxy row:...

    Daiichi-Ranbaxy row: HC allows sale of Singh brothers' firms

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-05-10T16:51:34+05:30  |  Updated On 10 May 2018 4:51 PM IST
    Daiichi-Ranbaxy row: HC allows sale of Singh brothers firms



    New Delhi: The Delhi High Court today allowed the sale of unencumbered shares of the firms of former promoters of India's Ranbaxy Laboratories Ltd in listed companies to repay the Rs 3,500 crore arbitration award in favour of Japanese pharma major Daiichi Sankyo.

    Justice Jayant Nath also directed the debtors to fully cooperate with the chartered accountant (CA), who was appointed a local commissioner in the matter, to sell these shares at the stock exchange.

    The court said the proceeds should be deposited with the registrar general of the High Court and listed the matter for further hearing on May 14.

    The order came after the CA submitted a report on May 8 giving the list of shares of the Singh brothers -- Malvinder and Shivinder, their family members and firms including RHC Holding Pvt Ltd and Oscar Investments Ltd, in listed companies.

    "The local commissioner/CA is directed to sell the entire lot of unemcumbered shares of the respondents, other than respondent number 1 (Malvinder Singh) in listed companies," the high court said.

    The counsel for the Singh brothers told the court that the Debt Recovery Tribunal had ordered a stay on the sale of unencumbered assets of Malvinder Singh in a separate case by the Yes Bank. The high court then sent a notice to the Yes Bank seeking its response.

    The court also issued notice to Daiichi on a plea by the brothers seeking a stay on the enforcement proceedings, as a Singapore court has reserved its judgment in an appeal by them against Daiichi's award.

    Singh brothers' advocate said the judgment of the Singapore court was expected in June and the proceedings to enforce the award here should be stayed till then.

    The Delhi High Court had earlier ordered the attachment of all unencumbered assets of RHC Holdings Pvt Ltd and Oscar Investments Pvt Ltd.

    A Singapore tribunal had in April 2016 passed the award in Daiichi's favour holding that the brothers had concealed information that their company was facing probe by the US Food and Drug Administration and the Department of Justice, while selling its shares.

    The high court on January 31 had upheld the international arbitral award passed in the favour of Daiichi and paved the way for enforcement of the 2016 tribunal award against the brothers who had sold their shares in Ranbaxy to Daiichi in 2008 for Rs 9,576.1 crore. Sun Pharmaceuticals Ltd had later acquired the company from Daiichi.

    It had however said that the award was not enforceable against five minors, who were also shareholders in Ranbaxy, saying they cannot be held guilty of having perpetuated a fraud either themselves or through any agent.

    Daiichi had moved the high court here seeking direction to the brothers to take steps towards paying its Rs 3,500 crore arbitration award, including depositing the amount. It had also urged the court to attach their assets, which may be used to recover the award.

    On February 16, the Supreme Court had dismissed Singh brothers' appeal against the high court verdict upholding the international arbitral award.

    Singhs' counsel had argued that the award granted consequential damages which were beyond the jurisdiction of the arbitral tribunal and the award cannot be enforced under the provision of the Arbitration Act.

    They had claimed that Daiichi was fully aware of all facts and still chose to retain the Ranbaxy shares, instead of terminating the agreement and returning them.


    agreementarbitrationDaiichi SankyoDelhi high courtJayant NathMalvinder and ShivinderpavedRanbaxyRanbaxy laboratoriesRHC Holdings Pvt LtdSun PharmaceuticalsSupreme Courtterminatingunencumbered
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok